Thirty patients had tumor markers within 30 days of starting treatment and periodically while on treatment (pancreastatin, gastrin, glucagon, neurotensin; metenephrines for pheochromocytoma/paraganlgioma). This evidence concerns the gene CHGA and hereditary pheochromocytoma-paraganglioma.